Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akesis Pharmaceuticals has reported that the FDA has accepted its investigational new drug application for a novel vanadium compound, to test its safety and efficacy in patients with type II diabetes.
Subscribe to our email newsletter
DGD Research of San Antonio has begun screening patients in a Phase IIa, controlled US clinical trial measuring efficacy (using the gold-standard euglycemic-hyperinsulinemic clamping procedure), as well as pharmacokinetic parameters, safety and tolerability of AKP-020 in diabetic patients.
Jay Lichter, president and CEO of Akesis, said: “We are extremely pleased to have received clearance for investigational new drug (IND)application and guidance from the FDA to begin our clinical study with AKP-020. Our development program is on schedule, and we expect to dose our first patient before the end of 2007.”